An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalAsthma, Bronchial
- Registration Number
- NCT00092885
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.
- Detailed Description
The duration of treatment is 2 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 831
Inclusion Criteria
- Non-smoker
- A 2-year documented history of seasonal allergic rhinitis
- A 1-year documented history of chronic asthma
- Positive allergy testing
Exclusion Criteria
- Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Daily Rhinitis Symptoms score; the Daytime Nasal Symptoms score and Nighttime Symptoms score
- Secondary Outcome Measures
Name Time Method (1) Rhinoconjunctivitis Quality-of-Life Questionnaire overall score; (2) Global Evaluation of Allergic Rhinitis by Patient; (3) Global Evaluation of Allergic Rhinitis by Physician